During the past two decades, there have been numerous attempts at using animals in order
to produce recombinant human proteins and monoclonal antibodies. However, it is only …

Transgenic animal bioreactors can produce therapeutic proteins with high value for
pharmaceutical use. In this paper, we compared different systems capable of producing …

Recombinant blood clotting factor VIII is one of the most complex proteins for industrial
manufacturing due to the low efficiency of its gene transcription, massive intracellular loss of …

Beginning in 1931, an inbred rabbit colony was developed at the Phipps Institute for the
Study, Treatment and Prevention of Tuberculosis at the University of Pennsylvania. This …

Zinc-finger nucleases and transcription activator-like effector nucleases are novel gene-
editing platforms contributing to redefine the boundaries of modern biological research …

Background: Current manufacturing methods for recombinant human factor VIII (rFVIII) within
mammalian cell cultures are inefficient, hampering the production of sufficient amounts for …

Somatic cell cloning technology in mammals promotes the multiplication of productively-
valuable genetically engineered individuals, and consequently allows also for …

The present invention relates to the therapeutic application of the Kazal-type serine protease
inhibitor Infestin or domains thereof or modified Kazal-type serine protease inhibitors based …

Transgenic animals are used extensively in the study of in vivo gene function, as models for
human diseases and in the production of biopharmaceuticals. The technology behind …

The aim of our study was to compare the hFVIII mRNA expression in different organs,
pathological changes and selected haematological and biochemical blood parameters …